ArticleMolecular cancer research : MCR2019
The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 83 citations in OpenAlex.
- Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab-paclitaxel.International journal of cancer · 2026Article
- NTRK2 promotes malignant progression and paclitaxel resistance of lung adenocarcinoma through targeting MYC/ABCF1 axis.Translational oncology · 2026Article
- Plexin Domain Containing 2, a Protein Specifically Expressed and Elevated in Human Pancreatic Cancer Tissue and Serum, Influences Cell Proliferation by Correlating With Cortactin.Cancer medicine · 2025Article
- Review
- Proteomics in pancreatic cancer.Biomarker research · 2025Review
- Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy.Discover oncology · 2025Review
- Targeted mitochondrial therapy for pancreatic cancer.Translational oncology · 2025Review
- Functional screen identifies RBM42 as a mediator of oncogenic mRNA translation specificity.Nature cell biology · 2025Article
- c-Myc inhibition and p21 modulation contribute to unsymmetrical bisacridines-induced apoptosis and senescence in pancreatic cancer cells.Pharmacological reports : PR · 2025Article
- Zebrafish Congenital Heart Disease Models: Opportunities and Challenges.International journal of molecular sciences · 2024Review
- Enhancing precision in colorectal cancer surgery: development of an LGR5-targeting RSPO1 peptide mimetic as a contrast agent for intraoperative fluorescence molecular imaging.Cell cycle (Georgetown, Tex.) · 2024Article
- ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells.Journal of experimental & clinical cancer research : CR · 2024Article
- Glutamine addiction and therapeutic strategies in pancreatic cancer.World journal of gastrointestinal oncology · 2023Review
- Lobetyolin inhibits cell proliferation and induces cell apoptosis by downregulating ASCT2 in gastric cancer.Cytotechnology · 2023Article
- Momordicae Semen inhibits migration and induces apoptotic cell death by regulating c-Myc and CNOT2 in human pancreatic cancer cells.Scientific reports · 2023Article
- Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers-Improvements in Clinical Efficacy and Safety.Biomedicines · 2023Review
- MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition.The Journal of experimental medicine · 2023Article
- Expansion of human amniotic epithelial cells using condition cell reprogramming technology.Human cell · 2023Article
- Target c-Myc to treat pancreatic cancer.Cancer biology & therapy · 2022Article
- Assessment of spatial transcriptomics for oncology discovery.Cell reports methods · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 9 institutions in 1 country.
Erika ParasidoDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
George S AvetianDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
Aisha NaeemDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
Garrett GrahamDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.ORCID 0000-0002-1097-0962
Michael PishvaianDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
Eric GlasgowDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
Shaila MudambiDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
Yichien LeeDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
Chukwuemeka IhemelanduDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
Muhammad ChoudhryDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
Ivana PeranDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.ORCID 0000-0001-7399-7452
Partha P BanerjeeDepartment of Biochemistry, Molecular and Cell Biology, Georgetown University Medical Center, Washington, D.C.
Maria Laura AvantaggiatiDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
Kirsten BryantDepartment of Pharmacology, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0003-4026-0942
Elisa BaldelliCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia.ORCID 0000-0002-6288-4599
Mariaelena PierobonCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia.
Lance LiottaCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia.
Emanuel PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia.
Stanley T FrickeCenter for Translational Imaging, Georgetown University Medical Center, Washington, D.C.
Aimy SebastianBiology and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, California.
Joseph CozzitortoDivision of Surgical Research, Department of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Gabriela G LootsBiology and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, California.
Deepak KumarDepartment of Pharmaceutical Sciences, Julius L. Chambers Biomedical/Biotechnology Research Institute (JLC-BBRI), North Carolina Central University, Durham, North Carolina.ORCID 0000-0002-0418-5116
Stephen ByersDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
Eric LondinComputational Medicine Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
Analisa DiFeoDivision of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0001-8319-6763
Goutham NarlaDivision of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Jordan WinterDivision of Surgical Research, Department of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Jonathan R BrodyDivision of Surgical Research, Department of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Olga RodriguezDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
Chris AlbaneseDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C. albanese@georgetown.edu.
Georgetown University · USGeorge Mason University · USLawrence Livermore National Laboratory · USSidney Kimmel Cancer Center · USUniversity of Michigan · USNorth Carolina Central University · USThomas Jefferson University · USUniversity Hospitals of Cleveland · USUniversity of North Carolina at Chapel Hill · US
Funding
X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Claudio Guillermo Giraudo · 1995 to 2026
$94.8MTissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI MARCUS S NOEL · 1990 to 2026
$71.5MTRAINING GRANT IN TUMOR BIOLOGYT32CA009686 · NCI · GEORGETOWN UNIVERSITY · PI ANNA Tate RIEGEL, DAVID J ROBBINS · 1996 to 2026
$10.8MInstitutional Career Development CoreKL2TR001432 · NCATS · GEORGETOWN UNIVERSITY · PI UMANS, JASON G · 2015 to 2024
$7.5MMolecular Determinants of Social Factors in Prostate CancerR01MD012767 · NIMHD · NORTH CAROLINA CENTRAL UNIVERSITY · PI KUMAR, DEEPAK · 2017 to 2021
$5.7MStructural and molecular determinants of protein phosphatase 2A in Alzheimer's DiseaseR01CA240993 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NARLA, GOUTHAM, TAYLOR, DEREK JAMES · 2019 to 2023
$3.4MMicroRNAs in African American Prostate CancerU01CA194730 · NCI · UNIVERSITY OF THE DISTRICT OF COLUMBIA · PI KUMAR, DEEPAK · 2015 to 2020
$1.8MNCATS NIH HHS KL2 TR001432NCI NIH HHS P30 CA051008NCI NIH HHS P30 CA056036NCI NIH HHS R01 CA240993NCI NIH HHS T32 CA009686NCI NIH HHS U01 CA194730NIMHD NIH HHS R01 MD012767
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and, very often, ineffective medical and surgical therapeutic options. The treatment of patients with advanced unresectable PDAC is restricted to systemic chemotherapy, a therapeutic intervention to which most eventually develop resistance. Recently, nab-paclitaxel (n-PTX) has been added to the arsenal of first-line therapies, and the combination of gemcitabine and n-PTX has modestly prolonged median overall survival. However, patients almost invariably succumb to the disease, and little is known about the mechanisms underlying n-PTX resistance. Using the conditionally reprogrammed (CR) cell approach, we established and verified continuously growing cell cultures from treatment-naïve patients with PDAC. To study the mechanisms of primary drug resistance, nab-paclitaxel-resistant (n-PTX-R) cells were generated from primary cultures and drug resistance was verified
Indexed as
Drug Resistance, NeoplasmUp-RegulationAgedAged, 80 and overAlbuminsAnimalsCarcinoma, Pancreatic DuctalFemaleGene Expression Regulation, NeoplasticHumansMaleMiceNeoplasm TransplantationPaclitaxelPancreatic NeoplasmsPrimary Cell Culture130-nm albumin-bound paclitaxelAlbuminsMYC protein, humanPaclitaxelProto-Oncogene Proteins c-myc
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.